Matching articles for "Rebyota"

Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023;  (Issue 1677)
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (Rebyota) was approved in 2022 for the same indication. Neither product is approved for acute treatment of CDI.
Med Lett Drugs Ther. 2023 May 29;65(1677):81-2 | Show Full IntroductionHide Full Introduction

Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence

   
The Medical Letter on Drugs and Therapeutics • March 6, 2023;  (Issue 1671)
The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic...
The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic treatment for a recurrent episode of CDI in adults. Rebyota is the first microbiome-based treatment to be approved for this indication. It is not approved for initial treatment of CDI. Fecal microbiota transplantation (FMT) has been used in patients with multiple CDI recurrences.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):35-6 | Show Full IntroductionHide Full Introduction